ClinicalTrials.gg
CompletedNCT01332292Updated Mar 23, 2017Results posted

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

A Phase 2 interventional study of Fluticasone furoate and Matching placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 5 sites in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
31st of 40
27 · median 102
Started
2010
with 6 others
Phase 2
12 of 40
none open now
Registered
17th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 31st largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 17th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate safety, tolerability, pharmacokinetics and serum cortisol levels.

Read the detailed description

This study will investigate the effect of dosing with fluticasone furoate 100 μg (micrograms) in asthmatic subjects aged 5-11 years of age. Fluticasone furoate is currently under development as the inhaled corticosteroid component of a combination product containing an inhaled corticosteroid and a long-acting beta-agonist.

The study will be a randomized two-way crossover, with a placebo control. During each treatment period subjects will receive a daily dose via a novel dry powder inhaler for 14 days. Approximately 26 subjects will be recruited to this study, with the aim that 20 will complete the study. Safety, tolerability, pharmacokinetics and serum cortisol levels will be investigated.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • inhalation profiles
  • pharmacokinetics
  • pharyngometry
  • asthma
  • pediatric subjects
  • GW685698
  • Fluticasone furoate
  • safety
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and pre-menarchial female subjects aged 5-11 years on the last planned treatment day are eligible for this study. Pre-menarchial females are defined as any female who has yet to begin menses and is considered Tanner Stage 2 or less.
  • Diagnosis of asthma at least 6 months prior to screening.
  • Patients must be controlled on their existing asthma treatment at screening as defined by a Childhood Asthma Control Test score of >19 and PEF (Peak Expiratory Flow) ≥80% predicted.
  • Apart from asthma, eczema and rhinitis, subjects should be healthy and suffer from no other significant medical conditions.
  • Subjects must be taking a stable regimen of a short acting beta-agonist inhaler on an as-need basis for at least 4 weeks prior to screening.
  • Subjects must weigh at least 15 kg (kilograms).
  • Subjects must demonstrate ability to accept and effectively use the fluticasone furoate devices using the demonstration kits provided to the site.
  • Subjects and parents/guardians must be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions. Parents/guardians must have the ability to read, write and record diary information collected throughout the study. They must also have the ability to manage study drug administration and PEF assessments.
  • A signed and dated written from at least one parent/guardian, and accompanying informed assent from the subject prior to admission to the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have changed their asthma medication within 4 weeks of screening or subjects currently being treated with inhaled or have received such treatment within 4 weeks of screening. In addition, subjects currently receiving (or have received within 4 weeks of screening) any of the following asthma therapies: theophyllines, long-acting inhaled beta-agonists or oral beta-agonists.
  • Any medical condition or circumstance making the volunteer unsuitable for participation in the study (e.g. history of life-threatening asthma).
  • Any abnormality identified on the screening medical assessment, including asthma exacerbation requiring systemic corticosteroids (oral, intramuscular, intravenous) or emergency room attendance within 3 months or asthma exacerbation requiring hospitalization within 6 months prior to screening.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Clinical visual evidence of oral candidiasis at screening.
  • Parent/guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g., inability to read, comprehend and write) which will limit the validity of consent to participate in this study.
  • Any adverse reaction including immediate or delayed to any beta-2-agonist, sympathomimetic drug, or any intranasal, inhaled or systemic corticosteroid therapy.
  • Known or suspected sensitivity to the constituents of the novel dry powder inhaler (i.e., lactose or magnesium stearate), for example, history of severe milk protein allergy.
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
  • Children who are wards of the state or government.
  • Evidence of clinically significant abnormality in the 12-lead (electrocardiogram) at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    COHORT 1 RANDOMISATION A

    (8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing

    Drug: Fluticasone furoate

  • Placebo comparator
    COHORT 1 RANDOMISATION B

    (8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing

    Drug: Matching placebo

  • Active comparator
    COHORT 2 RANDOMISATION A

    (5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing

    Drug: Fluticasone furoate

  • Placebo comparator
    COHORT 2 RANDOMISATION B

    (5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing

    Drug: Matching placebo

Interventions

  • Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.

  • DrugMatching placebo

    Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From the start of study medication until Week 11 (Visit 6)/Early Withdrawal

  2. Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  3. Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  4. Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of reticulocyte and RBCs at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  5. Hematocrit Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  6. Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  7. Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  8. Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  9. Albumin and Total Protein Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  10. Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  11. Total Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of total bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 44)

  12. Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period

    Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 44)

  13. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline and Day 14 of the Respective Treatment Period

    SBP and DBP were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.

    Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)

  14. Heart Rate at Baseline and Day 14 of the Respective Treatment Period

    Heart rate (HR) was measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.

    Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)

  15. Change From Baseline in the Indicated Electrocardiographic (ECG) Parameters at the Indicated Time Points on Day 14 of the Respective Treatment Period

    PR, QRS, QT, QTcB, QTcF, and RR were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period. Change from Baseline was calculated as the value at Day 14 minus the Baseline value. QTcB is the QT duration corrected for heart rate by Bazett's formula. QTcF is the QT duration corrected for heart rate by Fridericia's formula.

    Time frame: Baseline and Day 14 of the respective treatment period (up to Study Day 44)

Secondary outcomes

  1. AUC(0-t) on Day 14 of the Respective Treatment Period

    Area under the concentration-time (AUC(0-t)) curve from time zero (pre-dose) to the last time of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Due to non-quantifiable values, it was not possible to derive AUC(0-12).

    Time frame: Day 14 of the respective treatment period

  2. Cmax on Day 14 of the Respective Treatment Period

    Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period

  3. Tmax and t at Day 14 of the Respective Treatment Period

    tmax is defined as the time to reach the observed maximum concentration, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period

  4. Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period

    Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period

  5. Average Oropharyngeal Cross-sectional Area on Days 1 and 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Days 1 and 14 of the respective treatment period

  6. Distance of Assessment on Days 1 and 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of each treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Days 1 and 14 of the respective treatment period

  7. Oropharyngeal Volume on Days 1 and 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Days 1 and 14 of the respective treatment period

  8. Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.

    Time frame: Day 1 and Day 14 of the respective treatment period

  9. Inhalation Time on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.

    Time frame: Day 1 and Day 14 of the respective treatment period

  10. Inhaled Volume on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.

    Time frame: Day 1 and Day 14 of the respective treatment period

  11. Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.

    Time frame: Day 1 and Day 14 of the respective treatment period

  12. Total Emitted Dose (TED) on Days 1 and 14 of the Respective Treatment Period

    The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

    Time frame: Day 1 and Day 14 of the respective treatment period

  13. Ex-throat Dose (ETD) and ETD <2 Microns on Days 1 and 14 of the Respective Treatment Period

    The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

    Time frame: Day 1 and Day 14 of the respective treatment period

07

Results

Posted Sep 16, 2013

Participant flow

Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.

Treatment Period 1 (14 Days)
Participant flow — Treatment Period 1 (14 Days)
MilestoneSequence 1: FF 100 µg Followed by PlaceboSequence 2: Placebo Followed by FF 100 µg
Started1413
Completed1212
Not completed21
Withdrew: Adverse event10
Withdrew: Protocol violation11
Washout Period (>=7 Days)
Participant flow — Washout Period (>=7 Days)
MilestoneSequence 1: FF 100 µg Followed by PlaceboSequence 2: Placebo Followed by FF 100 µg
Started1212
Completed1212
Not completed00
Treatment Period 2 (14 Days)
Participant flow — Treatment Period 2 (14 Days)
MilestoneSequence 1: FF 100 µg Followed by PlaceboSequence 2: Placebo Followed by FF 100 µg
Started1212
Completed1111
Not completed11
Withdrew: Physician decision11

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From the start of study medication until Week 11 (Visit 6)/Early Withdrawal
Reported as:
Number · participants
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
participantsPlaceboFF 100 µg
Any AE48
Any SAE00
PrimaryBasophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · 10^9 cells per liter (GI/L)
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
10^9 cells per liter (GI/L)PlaceboFF 100 µg
Basophils, n=23, 210.022 ± 0.01530.022 ± 0.0154
Eosinophils, n=23, 210.308 ± 0.22040.252 ± 0.2182
Lymphocytes, n=23, 212.595 ± 0.78342.430 ± 0.6563
Monocytes, n=23, 210.280 ± 0.16690.270 ± 0.1204
Total neutrophils, n=23, 212.740 ± 1.20913.209 ± 1.3103
Platelets, n=23, 20266.4 ± 48.59263.3 ± 55.90
WBCs, n=23, 215.94 ± 1.6966.18 ± 1.513
PrimaryHemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Grams per liter (g/L)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Grams per liter (g/L)PlaceboFF 100 µg
Hemoglobin, n=23, 21129.1 ± 7.15129.6 ± 6.50
MCHC, n=23, 21336.4 ± 7.66336.6 ± 7.80
PrimaryReticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of reticulocyte and RBCs at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · 10^12 cells per liter (TI/L)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
10^12 cells per liter (TI/L)PlaceboFF 100 µg
Reticulocytes, n=23, 210.04952 ± 0.0244970.04499 ± 0.021309
RBCs, n=23, 214.43 ± 0.2774.46 ± 0.296
PrimaryHematocrit Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · percentage of red blood cells in blood
Hematocrit Values at Day 14 of the Respective Treatment Period
percentage of red blood cells in bloodPlaceboFF 100 µg
Hematocrit Values at Day 14 of the Respective Treatment Period0.3840 ± 0.026210.3854 ± 0.02296
PrimaryMean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · 10^15 femtoliters (fL) per cell
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
10^15 femtoliters (fL) per cellPlaceboFF 100 µg
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period86.8 ± 4.0586.9 ± 4.40
PrimaryMean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · 10^12 picograms (pg) per cell
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
10^12 picograms (pg) per cellPlaceboFF 100 µg
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period29.18 ± 1.27929.24 ± 1.458
PrimaryAlanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · International units per liter (IU/L)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
International units per liter (IU/L)PlaceboFF 100 µg
ALT, n=22, 2012.2 ± 3.0613.0 ± 6.04
ALP, n=22, 20257.8 ± 59.24260.7 ± 64.15
AST, n=22, 1926.8 ± 4.3926.1 ± 4.53
GGT, n=22, 2014.3 ± 3.5815.4 ± 4.50
PrimaryAlbumin and Total Protein Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Grams per liter
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Grams per literPlaceboFF 100 µg
Albumin, n=22, 2043.0 ± 2.2642.9 ± 1.83
Total protein, n=22, 2067.8 ± 2.9867.8 ± 2.57
PrimaryCalcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Millimoles per liter (mmol/L)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Millimoles per liter (mmol/L)PlaceboFF 100 µg
Calcium, n=20, 192.371 ± 0.07912.366 ± 0.0626
Chloride, n=22, 20105.2 ± 1.93104.7 ± 1.72
CO2 content/bicarbonate, n=20, 1917.4 ± 2.0417.8 ± 1.86
Glucose, n=22, 205.13 ± 0.6144.86 ± 0.319
Potassium, n=20, 194.24 ± 0.25644.24 ± 0.289
Sodium, n=22, 20138.3 ± 1.55137.4 ± 1.54
Urea/BUN, n=22, 204.66 ± 0.9934.83 ± 1.331
PrimaryTotal Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of total bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Micromoles per liter (µmol/L)
Total Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Micromoles per liter (µmol/L)PlaceboFF 100 µg
Total bilirubin, n= 22, 205.9 ± 2.275.6 ± 1.23
Creatinine, n= 22, 2039.89 ± 7.77540.62 ± 8.421
Uric acid, n= 22, 20237.7 ± 65.46234.5 ± 70.97
PrimaryPeak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period

Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · liters/minute
Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
liters/minutePlaceboFF 100 µg
Day 1, Baseline, n=25, 25242.3 ± 77.68238.4 ± 64.98
Day 1, 15 minutes post-dose, n=25, 25242.1 ± 78.98238.2 ± 58.97
Day 1, 30 minutes post-dose, n=25, 25249.2 ± 78.07246.0 ± 62.65
Day 1, 1 hour post-dose, n=25, 25247.7 ± 72.54247.0 ± 64.75
Day 1, 2 hours post-dose, n=25, 25252.3 ± 89.08252.6 ± 61.77
Day 14, Pre-dose, n=24, 23242.0 ± 73.60240.6 ± 83.88
Day 14, 30 minutes post-dose, n=23, 23246.1 ± 81.17238.8 ± 88.78
Day 14, 1 hours post-dose, n=23, 23247.0 ± 77.95237.6 ± 78.66
Day 14, 2 hours post-dose, n=23, 23249.5 ± 74.09242.3 ± 72.02
Day 14, 4 hours post-dose, n=23, 23250.6 ± 82.43246.2 ± 70.43
Day 14, 7 hours post-dose, n=23, 23246.3 ± 79.07232.1 ± 59.82
Day 14, 12 hours post-dose, n=23, 23241.9 ± 75.80245.6 ± 76.68
PrimarySystolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline and Day 14 of the Respective Treatment Period

SBP and DBP were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.

Time frame:
Baseline and Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Millimeters of mercury (mmHg)
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline and Day 14 of the Respective Treatment Period
Millimeters of mercury (mmHg)PlaceboFF 100 µg
Day 1 SBP, Predose, n=25, 26103.1 ± 9.29102.9 ± 9.68
Day 1 SBP, 30 minutes, n=25, 26101.2 ± 8.57103.8 ± 10.44
Day 1 SBP, 1 hour, n=25, 26102.7 ± 11.11105.2 ± 11.19
Day 1 SBP, 2 hours, n=25, 26102.9 ± 9.98103.9 ± 9.04
Day 14 SBP, Predose, n=24, 23101.8 ± 8.04102.1 ± 9.92
Day 14 SBP, 1 hour, n=23, 23102.6 ± 9.14103.1 ± 8.04
Day 14 SBP, 4 hours, n=23, 23102.0 ± 9.07102.7 ± 9.43
Day 14 SBP, 7 hours, n=23, 23103.4 ± 9.34103.9 ± 9.88
Day 14 SBP, 12 hours, n=23, 23103.2 ± 7.42106.3 ± 10.61
Day 1 DBP, Predose, n=25, 2662.0 ± 9.7161.7 ± 7.66
Day 1 DBP, 30 minutes, n=25, 2663.0 ± 9.0962.6 ± 6.39
Day 1 DBP, 1 hour, n=25, 2661.4 ± 8.6962.3 ± 8.73
Day 1 DBP, 2 hours, n=25, 2663.0 ± 8.3461.2 ± 8.39
Day 14 DBP, Predose, n=24, 2361.3 ± 6.9161.4 ± 6.81
Day 14 DBP, 1 hour, n=23, 2363.9 ± 10.1462.7 ± 6.88
Day 14 DBP, 4 hours, n=23, 2360.4 ± 8.8160.5 ± 6.73
Day 14 DBP, 7 hours, n=23, 2361.8 ± 9.2762.3 ± 8.23
Day 14 DBP, 12 hours, n=23, 2362.0 ± 8.1063.9 ± 8.68
PrimaryHeart Rate at Baseline and Day 14 of the Respective Treatment Period

Heart rate (HR) was measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period.

Time frame:
Baseline and Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · Beats per minute
Heart Rate at Baseline and Day 14 of the Respective Treatment Period
Beats per minutePlaceboFF 100 µg
Day 1, Baseline, n=25, 2678.7 ± 13.1875.9 ± 11.48
Day 1, 30 minutes, n=25, 2678.5 ± 13.9975.5 ± 10.90
Day 1, 1 hour, n=25, 2678.6 ± 12.6277.6 ± 11.49
Day 1, 2 hours, n=25, 2680.6 ± 13.3079.6 ± 11.78
Day 14, Predose, n=24, 2376.8 ± 13.5274.5 ± 10.60
Day 14, 1 hour, n=23, 2380.3 ± 14.7676.2 ± 8.60
Day 14, 4 hours, n=23, 2378.2 ± 10.4677.7 ± 9.77
Day 14, 7 hours, n=23, 2383.1 ± 14.6581.2 ± 12.13
Day 14, 12 hours, n=23, 2383.6 ± 11.7081.1 ± 10.71
SecondaryAUC(0-t) on Day 14 of the Respective Treatment Period

Area under the concentration-time (AUC(0-t)) curve from time zero (pre-dose) to the last time of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Due to non-quantifiable values, it was not possible to derive AUC(0-12).

Time frame:
Day 14 of the respective treatment period
Reported as:
Geometric mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) on Day 14 of the Respective Treatment Period
picograms*hour per milliliter (pg*hr/mL)PlaceboFF 100 µg
AUC(0-t) on Day 14 of the Respective Treatment Period—91.29 (63.24 to 131.78)
SecondaryCmax on Day 14 of the Respective Treatment Period

Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Cmax on Day 14 of the Respective Treatment Period
picograms per milliliter (pg/mL)PlaceboFF 100 µg
Cmax on Day 14 of the Respective Treatment Period—24.68 (20.24 to 30.10)
SecondaryTmax and t at Day 14 of the Respective Treatment Period

tmax is defined as the time to reach the observed maximum concentration, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period
Reported as:
Mean · hours
Tmax and t at Day 14 of the Respective Treatment Period
hoursPlaceboFF 100 µg
tmax—0.863 ± 0.7926
t—6.953 ± 4.0875
SecondarySerum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period

Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period
Reported as:
Geometric mean · nanomoles per Liter
Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
nanomoles per LiterPlaceboFF 100 µg
Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period178.76 (157.43 to 202.97)150.41 (132.91 to 170.22)
SecondaryAverage Oropharyngeal Cross-sectional Area on Days 1 and 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Days 1 and 14 of the respective treatment period
Reported as:
Mean · centimeters squared (cm^2)
Average Oropharyngeal Cross-sectional Area on Days 1 and 14 of the Respective Treatment Period
centimeters squared (cm^2)PlaceboFF 100 µg
Day 1, n=14, 184.06 ± 1.8754.24 ± 1.677
Day 14, n= 12, 125.49 ± 1.5864.58 ± 1.497
SecondaryDistance of Assessment on Days 1 and 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of each treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Days 1 and 14 of the respective treatment period
Reported as:
Mean · centimeters (cm)
Distance of Assessment on Days 1 and 14 of the Respective Treatment Period
centimeters (cm)PlaceboFF 100 µg
Day 1, n=14, 1818.63 ± 1.73618.69 ± 1.432
Day 14, n= 12, 1219.37 ± 1.82318.61 ± 1.942
SecondaryOropharyngeal Volume on Days 1 and 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Days 1 and 14 of the respective treatment period
Reported as:
Mean · cubic centimeters (cm^3)
Oropharyngeal Volume on Days 1 and 14 of the Respective Treatment Period
cubic centimeters (cm^3)PlaceboFF 100 µg
Day 1, n=14, 1874.19 ± 32.40278.86 ± 31.092
Day 14, n= 12, 12106.31 ± 33.18886.22 ± 34.363
SecondaryAverage Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · Liters per minute (L/min)
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Days 1 and 14 of the Respective Treatment Period
Liters per minute (L/min)PlaceboFF 100 µg
Day 1 Average flow rate, n=21, 2035.38 ± 11.44134.65 ± 10.840
Day 14 Average flow rate, n=21, 2236.25 ± 11.24336.17 ± 12.772
Day 1 PIFR, n=21, 2051.83 ± 17.28652.90 ± 16.028
Day 14 PIFR, n=21, 2255.70 ± 16.58954.76 ± 17.986
SecondaryInhalation Time on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · Seconds
Inhalation Time on Days 1 and 14 of the Respective Treatment Period
SecondsPlaceboFF 100 µg
Day 1, n=21, 201.71 ± 0.5341.93 ± 0.861
Day 14, n= 21, 221.60 ± 0.8021.61 ± 0.858
SecondaryInhaled Volume on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · Liters
Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
LitersPlaceboFF 100 µg
Day 1, n=21, 200.99 ± 0.4611.07 ± 0.480
Day 14, n= 21, 221.00 ± 0.5800.95 ± 0.541
SecondaryPeak Pressure Drop on Days 1 and 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · Kilopascal (kpa)
Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
Kilopascal (kpa)PlaceboFF 100 µg
Day 1, n=21, 202.44 ± 1.6302.53 ± 1.560
Day 14, n= 21, 222.78 ± 1.5432.74 ± 1.609
SecondaryTotal Emitted Dose (TED) on Days 1 and 14 of the Respective Treatment Period

The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · micrograms
Total Emitted Dose (TED) on Days 1 and 14 of the Respective Treatment Period
microgramsPlaceboFF 100 µg
Day 1, Nominal TED, n=0, 20—85.35 ± 1.576
Day 14, Nominal TED, n=0, 22—85.57 ± 1.857
Day 1, Minimum TED, n=0, 20—84.84 ± 1.617
Day 14, Minimum TED, n=0, 22—85.17 ± 1.905
Day 1, Maximum TED, n=0, 20—85.86 ± 1.639
Day 14, Maximum TED, n=0, 22—85.97 ± 1.861
SecondaryEx-throat Dose (ETD) and ETD <2 Microns on Days 1 and 14 of the Respective Treatment Period

The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

Time frame:
Day 1 and Day 14 of the respective treatment period
Reported as:
Mean · micrograms
Ex-throat Dose (ETD) and ETD <2 Microns on Days 1 and 14 of the Respective Treatment Period
microgramsPlaceboFF 100 µg
Day 1, Nominal ETD, n=0, 17—29.37 ± 2.874
Day 14, Nominal ETD, n=0, 12—29.83 ± 2.528
Day 1, Minimum ETD, n=0, 17—28.47 ± 3.241
Day 14, Minimum ETD, n=0, 12—29.35 ± 2.664
Day 1, Maximum ETD, n=0, 17—30.26 ± 2.598
Day 14, Maximum ETD, n=0, 12—30.26 ± 2.472
Day 1, ETD <2 microns, n=0, 17—5.13 ± 0.498
Day 14, ETD <2 microns, n=0, 12—5.07 ± 0.455
Day 1, Minimum ETD <2 microns, n=0, 17—4.96 ± 0.459
Day 14, Minimum ETD <2 microns, n=0, 12—4.99 ± 0.448
Day 1, Maximum ETD <2 microns, n=0, 17—5.30 ± 0.559
Day 14, Maximum ETD <2 microns, n=0, 12—5.17 ± 0.476
PrimaryChange From Baseline in the Indicated Electrocardiographic (ECG) Parameters at the Indicated Time Points on Day 14 of the Respective Treatment Period

PR, QRS, QT, QTcB, QTcF, and RR were measured at Baseline and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1 for each period. Change from Baseline was calculated as the value at Day 14 minus the Baseline value. QTcB is the QT duration corrected for heart rate by Bazett's formula. QTcF is the QT duration corrected for heart rate by Fridericia's formula.

Time frame:
Baseline and Day 14 of the respective treatment period (up to Study Day 44)
Reported as:
Mean · milliseconds (msec)
Change From Baseline in the Indicated Electrocardiographic (ECG) Parameters at the Indicated Time Points on Day 14 of the Respective Treatment Period
milliseconds (msec)PlaceboFF 100 µg
Day 1 PR Interval, 30 minutes, n=25, 266.4 ± 6.377.5 ± 7.54
Day 1 PR Interval, 1 hour, n=25, 267.3 ± 6.688.4 ± 7.17
Day 1 PR Interval, 2 hours, n=25, 268.0 ± 8.619.5 ± 10.48
Day 14 PR Interval, Predose, n=24, 237.8 ± 6.769.6 ± 9.82
Day 14 PR Interval, 1 hour, n=23, 238.7 ± 6.748.3 ± 6.03
Day 14 PR Interval, 4 hours, n=23, 236.4 ± 3.708.9 ± 6.86
Day 14 PR Interval, 7 hour, n=23, 238.3 ± 6.5610.2 ± 10.09
Day 14 PR Interval, 12 hours, n=22, 237.2 ± 7.509.7 ± 6.54
Day 1 QRS Interval, 30 minutes, n=25, 264.6 ± 3.465.2 ± 4.70
Day 1 QRS Interval, 1 hour, n=25, 264.1 ± 2.844.4 ± 3.86
Day 1 QRS Interval, 2 hours, n=25, 264.0 ± 2.644.5 ± 3.61
Day 14 QRS Interval, Predose, n=24, 234.2 ± 3.714.7 ± 4.29
Day 14 QRS Interval, 1 hour, n=23, 235.7 ± 3.545.3 ± 4.71
Day 14 QRS Interval, 4 hours, n=23, 235.6 ± 3.854.9 ± 3.93
Day 14 QRS Interval, 7 hours, n=23, 236.1 ± 5.254.3 ± 4.22
Day 14 QRS Interval, 12 hours, n=23, 235.0 ± 4.704.8 ± 4.02
Day 1 QT Interval, 30 minutes, n=25, 269.8 ± 8.1410.5 ± 9.57
Day 1 QT Interval, 1 hour, n=25, 2613.1 ± 11.0412.7 ± 11.53
Day 1 QT Interval, 2 hours, n=25, 2617.5 ± 13.8815.5 ± 13.83
Day 14 QT Interval, Predose, n=24, 2312.5 ± 9.8115.5 ± 13.34
Day 14 QT Interval, 1 hour, n=23, 2311.4 ± 6.4515.9 ± 11.11
Day 14 QT Interval, 4 hours, n=23, 2313.3 ± 9.6516.7 ± 12.52
Day 14 QT Interval, 7 hours, n=23, 2314.7 ± 10.9415.3 ± 11.93
Day 14 QT Interval, 12 hours, n=23, 2314.7 ± 10.4224.8 ± 14.93
Day 1 QTcB Interval, 30 minutes, n=25, 2615.4 ± 14.4414.2 ± 11.64
Day 1 QTcB Interval, 1 hour, n=25, 2617.3 ± 13.4617.7 ± 13.18
Day 1 QTcB Interval, 2 hours, n=25, 2613.6 ± 11.0718.2 ± 17.54
Day 14 QTcB Interval, Predose, n=24, 2320.7 ± 15.5417.9 ± 14.92
Day 14 QTcB Interval, 1 hour, n=23, 2316.6 ± 9.4316.2 ± 9.71
Day 14 QTcB Interval, 4 hours, n=23, 2314.7 ± 9.1316.8 ± 9.23
Day 14 QTcB Interval, 7 hours, n=23, 2314.5 ± 10.1419.6 ± 12.03
Day 14 QTcB Interval, 12 hours, n=23, 2313.8 ± 10.7018.5 ± 15.70
Day 1 QTcF Interval, 30 minutes, n=25, 2610.8 ± 9.3111.8 ± 9.30
Day 1 QTcF Interval, 1 hour, n=25, 2611.6 ± 9.5712.6 ± 10.00
Day 1 QTcF Interval, 2 hours, n=25, 2610.4 ± 8.3615.4 ± 12.88
Day 14 QTcF Interval, Predose, n=24, 2314.2 ± 9.9212.6 ± 10.99
Day 14 QTcF Interval, 1 hour, n=23, 239.3 ± 6.0911.4 ± 9.56
Day 14 QTcF Interval, 4 hours, n=23, 237.8 ± 6.9715.7 ± 7.41
Day 14 QTcF Interval, 7 hours, n=23, 239.3 ± 7.7715.0 ± 9.51
Day 14 QTcF Interval, 12 hours, n=23, 238.8 ± 5.8415.8 ± 11.61
Day 1 RR Interval, 30 minutes, n=25, 2670.4 ± 66.4754.2 ± 44.61
Day 1 RR Interval, 1 hour, n=25, 2693.5 ± 64.9790.7 ± 52.94
Day 1 RR Interval, 2 hours, n=25, 26102.0 ± 61.6680.4 ± 71.51
Day 14 RR Interval, Predose, n=24, 23106.0 ± 73.20103.5 ± 78.48
Day 14 RR Interval, 1 hour, n=23, 2392.5 ± 64.4587.7 ± 63.30
Day 14 RR Interval, 4 hours, n=23, 2392.1 ± 65.9363.6 ± 47.14
Day 14 RR Interval, 7 hours, n=23, 2389.6 ± 63.0674.5 ± 78.18
Day 14 RR Interval, 12 hours, n=23, 2394.4 ± 73.45110.3 ± 101.24

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/25 (0%)4/25 (16%)
FF 100 µg—0/26 (0%)8/26 (30.8%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboFF 100 µg
HeadacheNervous system disorders0/253/26
Upper respiratory tract infectionInfections and infestations1/251/26
Abdominal discomfortGastrointestinal disorders1/250/26
ToothacheGastrointestinal disorders1/251/26
Product taste abnormalGeneral disorders1/251/26
ArthralgiaMusculoskeletal and connective tissue disorders1/250/26
Acute tonsillitisInfections and infestations0/251/26
InfluenzaInfections and infestations0/251/26
Otitis externaInfections and infestations0/251/26
Otitis mediaInfections and infestations0/251/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µg/Placebo or Placebo/FF 100 µg
Mean8.2 ± 2.08
Sex: Female, Male
Sex: Female, Male(Participants)FF 100 µg/Placebo or Placebo/FF 100 µg
Female13
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FF 100 µg/Placebo or Placebo/FF 100 µg
African American/African Heritage9
White16
African American/African Heritage & White1
Unknown; Child Was Adopted1
08

Study locations

5 sites
  • GSK Investigational Site
    Cypress, California 90630, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 8 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2010
First posted
Apr 11, 2011
Start
May 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results delay requested
Mar 15, 2012
Results first posted
Sep 16, 2013
Last update
Mar 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01332292
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
May 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Sep 16, 2013
Last update
Mar 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion